OrbusNeich has introduced the Combo dual therapy stent, believed to be the worldâs first dual therapy stent to address delayed healing of the coronary artery associated with monotherapy drug eluting stents (DES), the current standard-of-care for the treatment of coronary artery disease (CAD). The launch of the Combo stent is in conjunction with the company's receipt of a CE mark for the product, and involves a sales roll-out in Europe and selected markets in the Asia-Pacific and Middle East regions.
The Combo dual therapy stent is the first stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of OrbusNeich's proven pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days. Nine-month outcomes from the REMEDEE study confirmed that the Combo stent s as effective as a monotherapy DES, with respect to in-stent late lumen loss at nine-month angiographic follow-up. These data were used to support CE mark approval for Combo.